Skip to main content

Table 5 Pathology results in comparison to other methods of assessment

From: Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography

Patient PIB-PET Pathology Criteria FDG-Qual FDG-Quant MRI
2 - CBD fvCBS tpvCBS tpvCBS fvCBS
3 - CBD fvCBS fvCBS fvCBS fvCBS
8 - CBD tpvCBS tpvCBS tpvCBS N/A
10 - PSP fvCBS fvCBS fvCBS tpvCBS
14 - Pick’s + DLB tpvCBS fvCBS fvCBS fvCBS
13 + AD + CBDa tpvCBS tpvCBS tpvCBS tpvCBS
18 + AD + DLB tpvCBS tpvCBS tpvCBS tpvCBS
19 + AD + DLB tpvCBS tpvCBS tpvCBS fvCBS
  1. aPatient 13 had evidence of AD and CBD pathology, but AD was the predominant pathology. AD, Alzheimer’s disease; CBD, corticobasal degeneration; fvCBS, frontal variant corticobasal syndrome; FDG-Qual, fluorodeoxyglucose PET qualitative (visual assessment); LBD, Lewy body disease; FDG-Quant, fluorodeoxyglucose PET quantitative (computed using ROI); PET, positron emission tomography; PSP, progressive supranuclear palsy; ROI, region of interest; tpvCBS, temporoparietal variant CBS. A ‘+’ or ‘-’ indicates positive or negative, respectively.